Stock LUCD LUCID DIAGNOSTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-06 EDT 		5-day change 1st Jan Change
1.04 USD +11.86% Intraday chart for Lucid Diagnostics Inc. +38.54% -26.24%
03-27 Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating MT
03-26 Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024

Evolution of the average Target Price on Lucid Diagnostics Inc.

Price target over the last 5 years

History of analyst recommendation changes

bb8bde2e2a41e4e1c0bfe284598.Wvvm-gvij1GTQj8bbWbzlq2Eu6ayyVT6rLDEnK36elM.CaPSl0-awBL_M2lRLyChzMWyzP_C-jCq3f6WyNvIPCkFjKutSoXkFusGDw~609147ca07e603a64eed5273584c43d5

Analyst Recommendations on Lucid Diagnostics Inc.

Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating MT
Needham Adjusts Price Target on Lucid Diagnostics to $2.80 From $2.60, Maintains Buy Rating MT
BTIG Adjusts Lucid Diagnostics' Price Target to $3.50 From $5, Keeps Buy Rating MT
Needham Adjusts Price Target on Lucid Diagnostics to $3.10 From $4.25, Maintains Buy Rating MT
Needham Cuts Price Target on Lucid Diagnostics to $4.25 From $5, 2023 Revenue Estimate to $15 Million From $20.8 Million; Buy Rating Kept MT
Needham Adjusts Lucid Diagnostics' Price Target to $5 From $7 on 'Peer Multiple Compression,' Reiterates Buy Rating MT
Canaccord Genuity Adjusts Lucid Diagnostics' Price Target to $12 From $18, Reiterates Buy Rating MT
Needham Adjusts Lucid Diagnostics' Price Target to $7 From $13, Citing Peer Multiple Compression, Lowered Revenue Expectation; Buy Rating Kept MT
Ascendiant Capital Starts Lucid Diagnostics at Buy With $16 Price Target MT
Needham Lowers Lucid Diagnostics' Price Target to $13 From $17, Citing 'Peer Multiple Contraction;' Buy Rating Kept MT
Canaccord Genuity Initiates Lucid Diagnostics at Buy Rating With $18 Price Target MT
BTIG Starts Lucid Diagnostics at Buy with $14 Price Target MT
Cantor Fitzgerald Starts Lucid Diagnostics at Overweight With $21 Price Target MT
Needham Starts Lucid Diagnostics at Buy With $17 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9297 USD
Average target price
3.833 USD
Spread / Average Target
+312.32%
High Price Target
8 USD
Spread / Highest target
+760.49%
Low Price Target
2.5 USD
Spread / Lowest Target
+168.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lucid Diagnostics Inc.

Cantor Fitzgerald
Needham & Co.
BTIG
Canaccord Genuity
Ascendiant Capital

Ratings for Lucid Diagnostics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LUCD Stock
  4. Consensus Lucid Diagnostics Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW